We partner with countries and work at the global level to assess supply and demand for health products and build markets that address the five A’s: affordability, availability, assured quality, appropriate design, and awareness.
Women want and need access to a variety of contraceptives to plan, space, and prevent pregnancies. PATH is expanding access and options with DMPA-SC (brand name Sayana® Press), an all-in-one contraceptive that puts women in charge of their reproductive health.
A national strategy focused on digital health, nutrition, and other high-impact interventions has dramatically improved health outcomes across India—but more work remains to be done.
A new resource sheds light on what’s needed to get ready for a new vaccine that, if approved, could help pregnant mothers protect their babies from a common cause of serious respiratory infections—respiratory syncytial virus.
At PATH, we connect local innovators and decision-makers with our global network of partners to develop responsive, human-centered solutions to health challenges.
Family planning leaders can draw from an established base of evidence to integrate DMPA-SC in efforts to address unmet need and increase access to contraception through a range of delivery channels.
Several thousands of health workers around the world have been trained to safely provide DMPA-SC injections in clinics, community locations, and villages, and even to support women to self-inject.